About Access Bio
Access Bio is a company based in Somerset (United States) founded in 2001. Access Bio has raised $22 million across 3 funding rounds from investors including Global Health Investment Corporation. The company has 52 employees. Access Bio offers products and services including CareStart COVID-19 Antigen Home Test, CareStart COVID-19 MDx RT-PCR, CareStart Malaria RDT, CareStart Dengue RDT, and CareStart Flu A&B Plus+. Access Bio operates in a competitive market with competitors including SD Biosensor, Lumos Diagnostics, Fluxergy, Module Innovations and DxGen, among others.
- Headquarter Somerset, United States
- Employees 52
- Stage Public
- SectorsHealthcare
- Website accessbio.net
- Legal Name Access Bio, Inc. Shs Korean Deposit Receipt Repr. 1 Shs
- Annual Revenue$21.61 M (USD)-72.22as on Dec 31, 2025
- Net Profit-$56.79 M (USD)-23514.5as on Dec 31, 2025
- EBITDA-$32.63 M (USD)-882.41as on Dec 31, 2025
- Total Equity Funding$22M (USD)
in 3 rounds
- Latest Funding Round$10M (USD), Series A
Nov 2020
- Investors
- Employee Count52
Products & Services of Access Bio
Access Bio offers a comprehensive portfolio of products and services, including CareStart COVID-19 Antigen Home Test, CareStart COVID-19 MDx RT-PCR, CareStart Malaria RDT, CareStart Dengue RDT, and CareStart Flu A&B Plus+.
Rapid antigen test for home-based COVID-19 detection.
RT-PCR kit for accurate COVID-19 virus detection.
Test for quick malaria parasite detection.
Rapid test for dengue virus identification.
Test for influenza A and B virus detection.
Funding Insights of Access Bio
Access Bio has successfully raised a total of $22M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $10 million completed in November 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $22M
- Total Rounds 3
- Last Round Series A — $10M
- First Round $12M
(May 2011)
- Investors Count 1
All 3 funding rounds of Access Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2020 | $10M | Series A | – | – | – |
| Apr 2016 | $8M | Post-IPO | – | – | |
| May 2011 | $12M | Series B | – | – | – |
1 investors in total: 1 institutional.
Investors in Access Bio
Access Bio has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Global Health Investment Corporation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Global health technologies are catalyzed by this nonprofit organization. | – | ghif.com | - |
Investor details for Access Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Access Bio
1 people are tracked at Access Bio (1 in leadership); the tracked headcount is 52.
| Name | Role | Group |
|---|---|---|
Young Choi | CEO | Leadership |
Complete people profiles for Access Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Access Bio
Access Bio is a publicly listed company on the KRX with ticker symbol 950130 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date31 May 2013
- Listed onKRX: 950130
- Listed entityAccess Bio, Inc. Shs Korean Deposit Receipt Repr. 1 shs
- Exchange sectorHealth technology
- ISINKR8840090003
- Share price2,240.00 KRW (-4.68% on the day) · 2026-10-08
- Market capitalisation78,789,388,160.00 KRW
- EPS (diluted, trailing year)-3,184.96 KRW
- Volume (last session)85,839
Financials of Access Bio
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 31.23B KRW | -82.06B KRW | -47.15B KRW |
| 2024 | 112.44B KRW | -347.5M KRW | 6.03B KRW |
| 2023 | 348.99B KRW | -3.18B KRW | 38.12B KRW |
| 2022 | 1,030.00B KRW | 346.71B KRW | 479.24B KRW |
| 2021 | 505.44B KRW | 189.81B KRW | 265.52B KRW |
Detailed financial statements for Access Bio
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Access Bio
4 dated milestones of Access Bio across 19 years, from founding to its latest funding, stage changes and deals.
- Founded Access Bio is founded.
- Funding First funding round of $12.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Series A, of $10.0M.
Competitors of Access Bio
Access Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as SD Biosensor, Lumos Diagnostics, Fluxergy, Module Innovations and DxGen, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| sdbiosensor.com | 2001 | Suwon-si, South Korea | – | – | Biosensors for point-of-care diagnostics are developed by SD Biosensor. | |
| lumosdiagnostics.com | 2017 | Carlsbad, United States | $40M | – | Diversified diagnostic assays and readers are developed for point-of-care use. | |
| fluxergy.com | 2011 | Irvine, United States | – | 74 | Provides diagnostic devices and software for clinical and veterinary point-of-care testing. | |
| moduleinnovations.com | 2014 | Pune, India | $799,890 | – | Diagnostics strip for bacterial detection | |
| dxgenco.com | 2016 | – | – | – | Point-of-care diagnostic products for diabetes and tuberculosis are provided. | |
| shanxmedtech.com | 2019 | Eindhoven, Netherlands | – | – | In vitro diagnostic platforms for antibiotic testing are provided. | |
| alantissciencesindia.com | 2020 | Manipal, India | – | – | Molecular biology and microbiology research services are provided for diagnostics. | |
| diasurebio.com | 2022 | Seoul, South Korea | $71,475 | – | Rapid antigen tests for infectious diseases are developed. | |
| novo-dx.com | 2022 | Boca Raton, United States | $1.2M | – | Point-of-care diagnostic tests are developed for in-home and clinical use. |
Detailed competitors of Access Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Access Bio
The website of Access Bio (accessbio.net) receives about 2.2K visits a month.
- Monthly visits2.2K
▼ 51.6% vs previous month
Websites whose visitors overlap most with Access Bio. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
moteclife.co.uk | moteclife.co.uk | 100% | – | #6,126,080 | – |
| globalpointofcare.abbott | 93% | 622.2K | #198,021 | View details | |
| orapharma.com | 90% | 1.9K | #8,533,356 | View details | |
malariasite.com | malariasite.com | 63% | – | #9,988,507 | – |
buzzoff.org | buzzoff.org | 62% | – | #7,716,328 | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 7 similar websites and full traffic analytics for Access Bio
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 7 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Access Bio
Complete news archive for Access Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Access Bio
10 companies that operate in the same segment as Access Bio (Infectious Diseases), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 | |
Clinical diagnostics and drug discovery for immune diseases are provided. | 2009 | Seattle, Washington, United States | USD 419.15 M | USD 276.98 M | 619 | |
Vaccines for infectious diseases are developed using cell-free protein synthesis. | 2013 | Foster City, California, United States | USD 347 M | – | 414 | |
Portable PCR diagnostics for infectious diseases are developed. | 2010 | San Jose, California, United States | USD 386.33 M | – | – | |
Developing glucan synthase inhibitors for the treatment of fungal infections. | 1999 | Jersey City, New Jersey, United States | USD 62.65 M | USD 20.6 M | 28 | |
Sherlock Biosciences is focused on molecular diagnostics development. | 2019 | Watertown, United States | USD 111 M | – | 33 | |
Provider of diagnostic solutions for systemic infections | 2016 | San Francisco, California, United States | USD 191.47 M | – | 54 | |
Developer of novel protein-based therapeutics using machine learning and biological engineering | 2018 | Somerville, Massachusetts, United States | USD 693 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Access Bio
Access Bio was founded in 2001 and raised its 1st funding round 10 years after it was founded.
Access Bio is headquartered in Somerset, United States.
Access Bio is a funded company, having raised a total of $22M across 3 funding rounds to date. The company's 1st funding round was a Series B of $12M, raised on May 2011.
Access Bio has 52 employees.
Annual revenue of Access Bio is $21.61M as on Dec 31, 2025.
Access Bio was founded in 2001 and is based in Somerset, United States. Operations focus on the medical diagnostics sector, where in vitro rapid tests, biosensors, and molecular diagnostic products are researched, developed, and manufactured for infectious disease detection. Point-of-care tests for malaria, dengue, G6PD deficiency, and pregnancy are provided, along with molecular diagnostics for Congenital Adrenal Hyperplasia and HPV infections.
Access Bio's top competitors include SD Biosensor, Lumos Diagnostics and Module Innovations.
Access Bio offers CareStart COVID-19 Antigen Home Test, CareStart COVID-19 MDx RT-PCR, CareStart Malaria RDT, CareStart Dengue RDT, and CareStart Flu A&B Plus+.
Yes, Access Bio is publicly traded on KRX under the ticker symbol 950130.
Access Bio has 1 investor. Key investors include Global Health Investment Corporation.
Access Bio operates through Access Bio, Inc..